Nextcure Stock Performance
| NXTC Stock | USD 1.17 0.03 2.50% |
The company secures a Beta (Market Risk) of 0.76, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, NextCure's returns are expected to increase less than the market. However, during the bear market, the loss of holding NextCure is expected to be smaller as well. At this point, NextCure has a negative expected return of -0.29%. Please make sure to verify NextCure's potential upside, rate of daily change, as well as the relationship between the Rate Of Daily Change and period momentum indicator , to decide if NextCure performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days NextCure has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
1 | Acquisition by Richman Michael of 300000 shares of NextCure at 12.59 subject to Rule 16b-3 | 09/16/2024 |
2 | Acquisition by Jones Elaine V of 14250 shares of NextCure at 1.62 subject to Rule 16b-3 | 09/26/2024 |
3 | NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting | 11/05/2024 |
4 | NextCure Reports Improved Financial Performance and Strategic Focus - TipRanks | 11/11/2024 |
5 | Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Ost... | 11/19/2024 |
6 | Acquisition by Feigal Ellen of 14250 shares of NextCure subject to Rule 16b-3 | 11/20/2024 |
7 | NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference | 11/26/2024 |
| Begin Period Cash Flow | 26.6 M |
NextCure |
NextCure Relative Risk vs. Return Landscape
If you would invest 147.00 in NextCure on August 30, 2024 and sell it today you would lose (30.00) from holding NextCure or give up 20.41% of portfolio value over 90 days. NextCure is currently does not generate positive expected returns and assumes 3.5865% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than NextCure, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
NextCure Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NextCure's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NextCure, and traders can use it to determine the average amount a NextCure's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0818
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NXTC |
Estimated Market Risk
| 3.59 actual daily | 31 69% of assets are more volatile |
Expected Return
| -0.29 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average NextCure is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NextCure by adding NextCure to a well-diversified portfolio.
NextCure Fundamentals Growth
NextCure Stock prices reflect investors' perceptions of the future prospects and financial health of NextCure, and NextCure fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NextCure Stock performance.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | (37.15 M) | ||||
| Shares Outstanding | 28.01 M | ||||
| Price To Earning | (25.44) X | ||||
| Price To Book | 0.43 X | ||||
| Price To Sales | 9.52 X | ||||
| Gross Profit | (54.2 M) | ||||
| EBITDA | (59.04 M) | ||||
| Net Income | (62.72 M) | ||||
| Cash And Equivalents | 185.49 M | ||||
| Cash Per Share | 6.68 X | ||||
| Total Debt | 6.61 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 33.87 X | ||||
| Book Value Per Share | 4.10 X | ||||
| Cash Flow From Operations | (52.97 M) | ||||
| Earnings Per Share | (2.10) X | ||||
| Market Capitalization | 32.77 M | ||||
| Total Asset | 128.04 M | ||||
| Retained Earnings | (324.48 M) | ||||
| Working Capital | 105.84 M | ||||
| Current Asset | 46.99 M | ||||
| Current Liabilities | 5.53 M | ||||
About NextCure Performance
By analyzing NextCure's fundamental ratios, stakeholders can gain valuable insights into NextCure's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if NextCure has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NextCure has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (51.33) | (53.89) | |
| Return On Tangible Assets | (0.49) | (0.51) | |
| Return On Capital Employed | (0.56) | (0.59) | |
| Return On Assets | (0.49) | (0.51) | |
| Return On Equity | (0.55) | (0.52) |
Things to note about NextCure performance evaluation
Checking the ongoing alerts about NextCure for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NextCure help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NextCure generated a negative expected return over the last 90 days | |
| NextCure may become a speculative penny stock | |
| NextCure has high historical volatility and very poor performance | |
| NextCure has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (62.72 M) with loss before overhead, payroll, taxes, and interest of (54.2 M). | |
| NextCure currently holds about 185.49 M in cash with (52.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| NextCure has a frail financial position based on the latest SEC disclosures | |
| Roughly 58.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference |
- Analyzing NextCure's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NextCure's stock is overvalued or undervalued compared to its peers.
- Examining NextCure's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NextCure's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NextCure's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NextCure's stock. These opinions can provide insight into NextCure's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for NextCure Stock analysis
When running NextCure's price analysis, check to measure NextCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NextCure is operating at the current time. Most of NextCure's value examination focuses on studying past and present price action to predict the probability of NextCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NextCure's price. Additionally, you may evaluate how the addition of NextCure to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |